NASDAQ:AQST Aquestive Therapeutics Q3 2026 Earnings Date & Estimates $4.76 +0.14 (+3.03%) Closing price 10/8/2026 04:00 PM EasternExtended Trading$4.76 0.00 (-0.11%) As of 10/8/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Aquestive Therapeutics is expected to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for November 5, 2026 at 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 4, 2026TimeAfter Market ClosesConference Call DateNovember 5, 2026Conference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Aquestive Therapeutics in Q3 2026Aquestive Therapeutics is expected to post earnings of -$0.10 per share on revenue of $11.02 million. In the same quarter a year earlier Aquestive Therapeutics reported -$0.14 per share on revenue of $12.81 million. Aquestive Therapeutics last reported on August 11, 2026, posting -$0.18 per share and missing the -$0.11 consensus estimate. Aquestive Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.10Expected Revenue$11.02 millionPrior-Year EPS-$0.14Prior-Year Revenue$12.81 millionExpected Revenue Growth-14.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.18 (Missed by -$0.08)Last Quarter Revenue$13.82 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Aquestive Therapeutics Q3 2026 Earnings FAQ When does Aquestive Therapeutics report Q3 2026 earnings? Aquestive Therapeutics (NASDAQ:AQST) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Aquestive Therapeutics' Q3 2026 earnings call? Aquestive Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Aquestive Therapeutics? Analysts expect Aquestive Therapeutics to post earnings of -$0.10 per share for Q3 2026. How much revenue is Aquestive Therapeutics expected to report? The consensus revenue estimate for Aquestive Therapeutics is $11.02 million for Q3 2026. Aquestive Therapeutics Earnings HeadlinesAquestive Therapeutics, Inc. (Nasdaq: AQST) Investor Alert: Schubert Jonckheer Investigating Possible False Statements Following 37% Stock DropOctober 7 at 9:30 AM | prnewswire.comAquestive Therapeutics, Inc. (NASDAQ:AQST) Stock Has Consensus Target Price of $9.17 According to AnalystsOctober 2, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Aquestive Therapeutics: The Market Is Already Pricing In Anaphylam's SuccessSeptember 30, 2026 | seekingalpha.comAquestive Therapeutics Strengthens Board of Directors with Appointment of Richard DalySeptember 29, 2026 | globenewswire.comComparing Aquestive Therapeutics (NASDAQ:AQST) & Oculis (NASDAQ:OCS)September 29, 2026 | americanbankingnews.comSee More Aquestive Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aquestive Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aquestive Therapeutics and other key companies, straight to your email. Email Address About Aquestive TherapeuticsAquestive Therapeutics (NASDAQ:AQST) is a pharmaceutical company that develops and commercializes medicines using proprietary drug-delivery technologies, including its PharmFilm platform. The company’s oral and buccal films are designed to dissolve in the mouth and may provide alternatives to conventional tablets, capsules, injections, or liquid formulations. Aquestive’s commercial and partnered products have included treatments for neurological conditions. Its portfolio includes Libervant (diazepam buccal film) for seizure clusters, Exservan (riluzole oral film) for amyotrophic lateral sclerosis, and Sympazan (clonazepam oral film) for certain seizure disorders. The company is also developing Anaphylm, an epinephrine sublingual film intended to address severe allergic reactions, along with other products and product candidates. The company was formerly known as MonoSol Rx and adopted the Aquestive Therapeutics name in 2018. Headquartered in Warren, New Jersey, Aquestive serves the U.S. market and works with commercial and development partners to support the availability of its products in international markets. Its leadership team is headed by Chief Executive Officer Daniel Barber.View Aquestive Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
